CA2854039A1 - Isoxazole treatments for diabetes - Google Patents

Isoxazole treatments for diabetes Download PDF

Info

Publication number
CA2854039A1
CA2854039A1 CA2854039A CA2854039A CA2854039A1 CA 2854039 A1 CA2854039 A1 CA 2854039A1 CA 2854039 A CA2854039 A CA 2854039A CA 2854039 A CA2854039 A CA 2854039A CA 2854039 A1 CA2854039 A1 CA 2854039A1
Authority
CA
Canada
Prior art keywords
substituted
hydrogen
unsubstituted
alkyl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2854039A
Other languages
English (en)
French (fr)
Inventor
Elhadji DIOUM
Jay Schneider
Doug FRANTZ
Hector AGUILAR
Melanie Cobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2854039A1 publication Critical patent/CA2854039A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2854039A 2011-11-23 2012-11-21 Isoxazole treatments for diabetes Abandoned CA2854039A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563419P 2011-11-23 2011-11-23
US61/563,419 2011-11-23
US201161566056P 2011-12-02 2011-12-02
US61/566,056 2011-12-02
PCT/US2012/066346 WO2013078376A2 (en) 2011-11-23 2012-11-21 Isoxazole treatments for diabetes

Publications (1)

Publication Number Publication Date
CA2854039A1 true CA2854039A1 (en) 2013-05-30

Family

ID=48470419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2854039A Abandoned CA2854039A1 (en) 2011-11-23 2012-11-21 Isoxazole treatments for diabetes

Country Status (9)

Country Link
US (2) US8722716B2 (https=)
EP (1) EP2782913A4 (https=)
JP (1) JP6190819B2 (https=)
CN (1) CN104350051B (https=)
AU (2) AU2012340622A1 (https=)
CA (1) CA2854039A1 (https=)
IL (1) IL232566A0 (https=)
MX (1) MX2014006286A (https=)
WO (1) WO2013078376A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
US20150297638A1 (en) * 2014-04-17 2015-10-22 Muhammad Ashraf Chemically induced pluripotent stem cells for safe therapeutic applications
JP2019503697A (ja) * 2016-02-04 2019-02-14 ネステク ソシエテ アノニム 明細書
JP6835899B2 (ja) * 2018-03-29 2021-02-24 株式会社 バイオミメティクスシンパシーズ Ｕｃｐ１発現細胞の培養方法
CN116270635B (zh) * 2021-12-13 2025-06-17 清华大学 杂环化合物用于减轻化疗药物引起的不良反应的用途
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001124A (en) 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
JP3542827B2 (ja) 1994-07-15 2004-07-14 帝国臓器製薬株式会社 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
US20060036451A1 (en) 2004-08-10 2006-02-16 Lundberg Steven W Patent mapping
JP2008515905A (ja) 2004-10-08 2008-05-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US8193225B2 (en) * 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009147990A1 (ja) * 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体

Also Published As

Publication number Publication date
AU2017202134A1 (en) 2017-04-20
IL232566A0 (en) 2014-06-30
JP6190819B2 (ja) 2017-08-30
EP2782913A2 (en) 2014-10-01
WO2013078376A3 (en) 2014-12-04
US20140315966A1 (en) 2014-10-23
WO2013078376A2 (en) 2013-05-30
JP2015510493A (ja) 2015-04-09
CN104350051B (zh) 2017-03-08
MX2014006286A (es) 2014-10-24
EP2782913A4 (en) 2015-10-28
CN104350051A (zh) 2015-02-11
AU2012340622A1 (en) 2014-05-22
US9221800B2 (en) 2015-12-29
US20130178506A1 (en) 2013-07-11
US8722716B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
AU2017202134A1 (en) Isoxazole treatments for diabetes
EP3596053B1 (en) Farnesoid x receptor agonists and uses thereof
Ge et al. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development
TW200942231A (en) Synthetic triterpenoids and methods of use in the treatment of disease
SG183817A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
US9212179B2 (en) Compositions and methods for the treatment of metabolic disorders
US11166924B2 (en) N-methyl-d-aspartate receptor allosteric modulators and methods for their use
EP3724173B1 (en) Compounds for the treatment of neuromuscular disorders
JP2022500393A (ja) ファルネソイドｘ受容体アゴニストおよびその使用
JP2019522666A (ja) ２型糖尿病の治療のためのアドレナリン受容体アゴニストの併用
US20160128985A1 (en) Methods and Compositions for the Treatment of Body Weight Related Disorders
US20160257675A1 (en) Compositions and methods for the treatment of metabolic disorders
EP3801515B1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
EP3664806B1 (en) 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS
US20140024683A1 (en) Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
US12440477B2 (en) Compounds for the treatment of neuromuscular disorders
US9468669B2 (en) Methods to treat dysregulated blood glucose disorders
JP7224303B2 (ja) 薬剤、組成物、及びそれに関連する方法
CN115087643B (zh) 稠和杂环类化合物及其制备方法和医药用途
EP3607948A1 (en) Tissue transglutaminase modulators for medicinal use
CN102786517B (zh) Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
WO2025193697A1 (en) Compositions and methods for treating metabolic disorders
WO2026060261A1 (en) Compositions and methods for treating metabolic disorders
WO2022109292A1 (en) Methods and materials for inhibiting cb1 activity
ERION QUN DANG*, PAUL D. VAN POELJE AND

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181121